HK1044895A1 - Methods for treating diabetes. - Google Patents

Methods for treating diabetes.

Info

Publication number
HK1044895A1
HK1044895A1 HK02106479A HK02106479A HK1044895A1 HK 1044895 A1 HK1044895 A1 HK 1044895A1 HK 02106479 A HK02106479 A HK 02106479A HK 02106479 A HK02106479 A HK 02106479A HK 1044895 A1 HK1044895 A1 HK 1044895A1
Authority
HK
Hong Kong
Prior art keywords
methods
type
diabetes
symptoms
treating diabetes
Prior art date
Application number
HK02106479A
Other languages
English (en)
Inventor
Andreas Sommer
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Publication of HK1044895A1 publication Critical patent/HK1044895A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
HK02106479A 1999-06-04 2002-09-02 Methods for treating diabetes. HK1044895A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/326,189 US6040292A (en) 1999-06-04 1999-06-04 Methods for treating diabetes
PCT/US2000/014163 WO2000074710A2 (en) 1999-06-04 2000-05-23 Methods for treating diabetes

Publications (1)

Publication Number Publication Date
HK1044895A1 true HK1044895A1 (en) 2002-11-08

Family

ID=23271175

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02106479A HK1044895A1 (en) 1999-06-04 2002-09-02 Methods for treating diabetes.

Country Status (16)

Country Link
US (1) US6040292A (ko)
EP (1) EP1183042B1 (ko)
JP (1) JP2003501397A (ko)
KR (1) KR100694737B1 (ko)
CN (1) CN1235637C (ko)
AT (1) ATE271880T1 (ko)
AU (1) AU780400B2 (ko)
CA (1) CA2373281C (ko)
DE (1) DE60012517T2 (ko)
ES (1) ES2222208T3 (ko)
HK (1) HK1044895A1 (ko)
IL (1) IL146868A0 (ko)
MX (1) MXPA01013384A (ko)
NO (1) NO324117B1 (ko)
WO (1) WO2000074710A2 (ko)
ZA (1) ZA200110408B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
KR100864120B1 (ko) * 2000-07-03 2008-10-16 브리스톨-마이어스스퀴브컴파니 가용성 ｃｔｌａ4 분자를 사용한 류마티스성 질환의 치료법
CA2422625A1 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
CN102860428A (zh) * 2004-12-30 2013-01-09 希尔氏宠物营养品公司 用于猫消费的组合物
EP2148695B1 (en) * 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity
EP2352514A4 (en) * 2008-10-29 2012-07-25 Univ Rockefeller METHOD AND KIT FOR DISEASE TREATMENT BY ADMINISTRATION OF THE PROTEIN BINDING TO AN INSULINARY GROWTH FACTOR 2
EP2413967A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Treatment of insulin-resistant disorders
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
WO2012024161A1 (en) * 2010-08-16 2012-02-23 Allergan, Inc. Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
GB9217696D0 (en) * 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
EP0642350A4 (en) * 1993-01-25 1995-06-28 Beth Israel Hospital PROCESS FOR MODIFICATION, DIAGNOSIS AND SCREENING OF IGF-I SENSITIVE CELL BARRIER CHARACTERISTICS.
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
ATE190499T1 (de) * 1993-08-03 2000-04-15 Celtrix Pharma Methode zur behandlung von reproduktionserkrankungen
WO1995008567A1 (en) * 1993-09-20 1995-03-30 Celtrix Pharmaceuticals, Inc. Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
JPH09509140A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
WO1995013824A1 (en) * 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering igf-i and igfbp-3
AU713275B2 (en) * 1994-07-20 1999-11-25 Celtrix Pharmaceuticals, Inc. IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes

Also Published As

Publication number Publication date
WO2000074710A3 (en) 2001-06-28
WO2000074710A2 (en) 2000-12-14
NO20015932L (no) 2002-01-31
AU780400B2 (en) 2005-03-17
IL146868A0 (en) 2002-08-14
ES2222208T3 (es) 2005-02-01
ZA200110408B (en) 2003-03-19
CA2373281C (en) 2010-01-12
CN1235637C (zh) 2006-01-11
KR20020020723A (ko) 2002-03-15
MXPA01013384A (es) 2003-09-04
EP1183042B1 (en) 2004-07-28
AU5041100A (en) 2000-12-28
DE60012517T2 (de) 2005-08-04
JP2003501397A (ja) 2003-01-14
NO20015932D0 (no) 2001-12-04
DE60012517D1 (de) 2004-09-02
EP1183042A2 (en) 2002-03-06
CA2373281A1 (en) 2000-12-14
CN1387440A (zh) 2002-12-25
NO324117B1 (no) 2007-08-27
KR100694737B1 (ko) 2007-03-14
US6040292A (en) 2000-03-21
ATE271880T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
HK1044895A1 (en) Methods for treating diabetes.
PT1409006E (pt) Misturas monodispersas e métodos de tratamento de diabetes
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
MY137350A (en) Glucagon-like peptide-1 analogs
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
HK1022701A1 (en) Exendin analogues, processes for their preparationand medicaments containing them exendin.
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
NO940180D0 (no) Anvendelse av IGF-I
WO1999053064A3 (en) Methods of delivering glp-1
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
UA32255A (uk) Спосіб лікування цукрового діабету
GB9818650D0 (en) Therapeutic compounds and methods of making and using the same
UA32295A (uk) Спосіб лікування порушень фертильності у хворих на цукровий діабет
UA88862C2 (en) Glucagon-like peptide-1 analogs
UA32254A (uk) Спосіб лікування хронічного пієлонефриту у хворих на цукровий діабет
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110523